Eurofins Scientific SE
PAR:ERF
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.19
61.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ERF stock under the Base Case scenario is 78.3 EUR. Compared to the current market price of 46.96 EUR, Eurofins Scientific SE is Undervalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eurofins Scientific SE
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ERF cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Eurofins Scientific SE
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Eurofins Scientific SE is a global leader in bio-analytical testing, offering a broad array of laboratory services that cater to a variety of sectors including food, pharmaceuticals, environmental, and consumer products. Founded in 1987, the company has expanded rapidly through strategic acquisitions and organic growth, positioning itself as a crucial partner for businesses aiming to ensure quality and compliance in their products. With its presence in over 50 countries and a workforce exceeding 50,000, Eurofins operates a network of highly specialized laboratories that leverage cutting-edge technology to deliver accurate, reliable testing services. Investors will appreciate the company’s ro...
Eurofins Scientific SE is a global leader in bio-analytical testing, offering a broad array of laboratory services that cater to a variety of sectors including food, pharmaceuticals, environmental, and consumer products. Founded in 1987, the company has expanded rapidly through strategic acquisitions and organic growth, positioning itself as a crucial partner for businesses aiming to ensure quality and compliance in their products. With its presence in over 50 countries and a workforce exceeding 50,000, Eurofins operates a network of highly specialized laboratories that leverage cutting-edge technology to deliver accurate, reliable testing services. Investors will appreciate the company’s robust growth trajectory, underpinned by a diverse customer base and an increasing global demand for testing services amid rising regulatory scrutiny.
As the world continues to grapple with health and safety challenges, Eurofins is poised to benefit from heightened awareness around food safety, environmental sustainability, and pharmaceutical integrity. The company’s commitment to innovation — investing significantly in research and development as well as state-of-the-art technology — ensures it remains at the forefront of scientific advancements. By focusing on quality assurance and risk assessment, Eurofins not only safeguards public health but also enhances the integrity of its clients’ products. For investors, Eurofins presents an attractive growth opportunity, with its solid operational foundations, strategic acquisitions, and resilience in navigating global markets making it a compelling addition to any investment portfolio.
Eurofins Scientific SE is a global group of laboratories known for providing laboratory services in various sectors. The company operates through several core business segments, including:
-
Food Testing: This segment focuses on ensuring food safety and quality, offering a range of services such as microbiological testing, chemical testing, allergen testing, nutrition analysis, and more. It helps clients comply with regulatory standards and improve product quality.
-
Environmental Testing: Eurofins provides analytical testing services for environmental samples including water, air, and soil. This segment supports compliance with environmental regulations and helps organizations manage environmental impact.
-
Pharmaceutical Testing: This segment serves pharmaceutical and biotech companies, providing services such as drug testing, method development, stability testing, and bioanalysis. Eurofins helps clients ensure that their products meet safety and efficacy standards.
-
Genomics: Eurofins offers genomic testing services, including DNA sequencing and genotyping. This segment caters to various industries, including healthcare and agriculture, focusing on genetic analysis and research.
-
Clinical Diagnostics: This segment provides laboratory testing services for clinical diagnostics, offering a range of tests related to disease detection, monitoring, and prevention. It plays a critical role in patient care and public health.
-
Biopharma Services: Eurofins offers a suite of biopharma services, including contract research and development services for biopharmaceuticals. This helps clients streamline their drug development process.
-
Consumer Products Testing: This segment includes testing services for consumer goods, ensuring compliance with safety standards, quality assurance, and regulatory requirements.
Through these segments, Eurofins Scientific SE positions itself as a leader in laboratory services, providing comprehensive solutions that cater to a diverse range of industries and regulatory needs.
Eurofins Scientific SE holds several unique competitive advantages over its rivals in the laboratory services and testing sectors. Here are some key advantages:
-
Extensive Network of Laboratories: Eurofins operates a vast network of laboratories across different countries, which allows them to provide localized services while benefiting from economies of scale. This broad geographic reach enhances their ability to meet diverse client needs quickly.
-
Diversified Service Portfolio: Eurofins offers a wide range of services, including environmental testing, food and feed testing, pharmaceutical testing, and clinical diagnostics. This diversification helps mitigate risks associated with dependence on a single market or sector, making the company more resilient to economic fluctuations.
-
Strong R&D Focus: The company invests significantly in research and development to innovate and improve existing testing methodologies, which keeps them ahead in terms of technological advancements. This ongoing investment enhances their capabilities and helps attract clients looking for reliable and cutting-edge testing solutions.
-
Accreditations and Certifications: Eurofins is known for maintaining high-quality standards and holds numerous accreditations and certifications across various industries. This reputation for quality assurance builds trust with clients and enhances their competitive positioning.
-
Strategic Acquisitions: Eurofins has a history of strategic acquisitions that allow them to quickly expand their capabilities and market presence. These acquisitions often bring specialized expertise and new technologies that can be integrated into Eurofins' existing operations, enhancing their service offerings.
-
Strong Client Relationships: The company has developed long-term relationships with many of its clients, particularly in sectors like pharmaceuticals and food safety, which often result in repeat business and a stable revenue base.
-
Scalability and Flexibility: Eurofins leverages its size and structure to quickly scale operations according to market demands. Their ability to respond flexibly to emerging market needs or crises (like a pandemic) gives them an edge over more rigid competitors.
-
Sustainability Initiatives: Eurofins is increasingly focusing on sustainability within their testing services, aligning with global trends toward environmental responsibility. This position can attract clients that prioritize sustainability in their supply chains.
-
Expertise and Talent Pool: The company boasts a highly skilled workforce with expertise across various scientific disciplines. This talent pool not only enhances service delivery but also drives innovation and high-quality results.
These competitive advantages, collectively, position Eurofins Scientific SE as a leader in the laboratory services industry, enabling it to better serve clients and withstand competitive pressures.
Eurofins Scientific SE, as a global leader in laboratory services, faces several risks and challenges that could impact its operations and growth in the near future:
-
Regulatory Compliance: The company operates in a heavily regulated environment, and any changes in regulations or failure to comply could lead to fines, sanctions, or disruptions in operations.
-
Market Competition: The laboratory services market is highly competitive, with both established firms and new entrants. Increased competition could lead to price wars and reduced margins.
-
Economic Volatility: Economic downturns can lead to decreased demand for testing services, especially in sectors like food safety, environmental testing, and pharmaceuticals.
-
Technological Advancements: The rapid pace of technological change necessitates continuous investment in new technologies and methodologies. Failure to keep up could result in loss of market share.
-
Supply Chain Disruptions: Global supply chain issues, which have been prevalent, can affect the availability and cost of materials needed for laboratory operations.
-
Cybersecurity Threats: As a company that handles sensitive data, Eurofins is at risk from cyberattacks, which can compromise data integrity and lead to legal challenges.
-
Labor Shortages: A shortage of skilled labor in the laboratory sector could lead to operational inefficiencies and difficulties in meeting customer demands.
-
Health Crises: The COVID-19 pandemic highlighted the vulnerability of the healthcare system. Future health crises could overwhelm testing capacities or shift market demand significantly.
-
Currency Fluctuations: As a global player, Eurofins is exposed to currency risks which can impact profitability from international operations.
-
Environmental and Social Governance (ESG) Pressures: Increasing focus on sustainability and corporate responsibility may require Eurofins to adapt its practices, which could involve significant investment and changes in strategy.
Handling these challenges will require strategic foresight, proactive risk management, and a commitment to innovation and quality.
Revenue & Expenses Breakdown
Eurofins Scientific SE
Balance Sheet Decomposition
Eurofins Scientific SE
Current Assets | 3.1B |
Cash & Short-Term Investments | 472.1m |
Receivables | 1.6B |
Other Current Assets | 977.3m |
Non-Current Assets | 7.8B |
Long-Term Investments | 83.6m |
PP&E | 2.3B |
Intangibles | 5.3B |
Other Non-Current Assets | 93.8m |
Current Liabilities | 2.1B |
Accounts Payable | 339.2m |
Accrued Liabilities | 320.2m |
Short-Term Debt | 200k |
Other Current Liabilities | 1.5B |
Non-Current Liabilities | 3.7B |
Long-Term Debt | 3.3B |
Other Non-Current Liabilities | 363.8m |
Earnings Waterfall
Eurofins Scientific SE
Revenue
|
6.7B
EUR
|
Cost of Revenue
|
-5.2B
EUR
|
Gross Profit
|
1.5B
EUR
|
Operating Expenses
|
-538.3m
EUR
|
Operating Income
|
942.4m
EUR
|
Other Expenses
|
-616.5m
EUR
|
Net Income
|
325.9m
EUR
|
Free Cash Flow Analysis
Eurofins Scientific SE
EUR | |
Free Cash Flow | EUR |
Eurofins delivered a positive third-quarter performance despite the reduction in COVID-related revenue that boosted 2021 figures. The comparison is now more normalized ('apples to apples'), and the outlook appears favorable, particularly in non-COVID areas like America and biopharma product testing. Challenges remain, especially in earlier biopharma phases and the European market, influenced by economic headwinds and consumer inflation impact. Nevertheless, Eurofins is showing resilience, with Asia indicating some areas of misclassified revenues. Strategic M&A activity continues with disciplined investment, aiming for EUR 250 million pro forma revenues. R&D investment persists, amplifying the role of AI across different segments. Revenue guidance remains in a range, due to currency uncertainties, and the company maintains its objective of 6.5% organic growth.
What is Earnings Call?
ERF Profitability Score
Profitability Due Diligence
Eurofins Scientific SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Eurofins Scientific SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ERF Solvency Score
Solvency Due Diligence
Eurofins Scientific SE's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Eurofins Scientific SE's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERF Price Targets Summary
Eurofins Scientific SE
According to Wall Street analysts, the average 1-year price target for ERF is 60.34 EUR with a low forecast of 42.42 EUR and a high forecast of 93.45 EUR.
Dividends
Current shareholder yield for ERF is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. The company operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain.
Officers
The intrinsic value of one ERF stock under the Base Case scenario is 78.3 EUR.
Compared to the current market price of 46.96 EUR, Eurofins Scientific SE is Undervalued by 40%.